FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Zacks Investment Research8/5/2026Neutral
FMS
Fresenius Medical Care CorporationNYSEHEALTHCAREMEDICAL CARE FACILITIES
Key Statistics
Market Cap
$12.51B
P/E Ratio
12.43
EPS
$1.89
Beta
0.84
52W High
$26.57
52W Low
$19.24
50-Day MA
$23.77
200-Day MA
$23.24
Dividend Yield
3.67%
Profit Margin
4.83%
Forward P/E
9.92
PEG Ratio
0.83
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.
Fundamentals
| Revenue (TTM) | $19.43B |
| Gross Profit (TTM) | $5.12B |
| EBITDA | $2.72B |
| Operating Margin | 10.80% |
| Return on Equity | 8.52% |
| Return on Assets | 3.98% |
| Revenue/Share (TTM) | $34.64 |
| Book Value | $27.29 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 0.64 |
| EV/Revenue | 1.054 |
| EV/EBITDA | 5.95 |
| Quarterly Earnings Growth (YoY) | 5.50% |
| Quarterly Revenue Growth (YoY) | 1.40% |
| Shares Outstanding | $532.22M |
| Float | $363.78M |
| % Insiders | 0.00% |
| % Institutions | 9.92% |
Historical Volatility
HV 10-Day
28.16%
HV 20-Day
27.71%
HV 30-Day
24.76%
HV 60-Day
25.77%
HV Rank
30.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($25.79 target)
1
Strong Buy1
Buy2
Hold1
Sell2
Strong SellLatest News
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Seeking Alpha8/4/2026Neutral
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.
MarketBeat8/4/2026Negative
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
WSJ8/4/2026Negative
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's decision to merely confirm, not raise, the full-year guidance.
Reuters8/4/2026Negative
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of market expectations and reaffirmed its full-year outlook, as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient treatment volumes.
Reuters8/3/2026Positive
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.
Proactive Investors7/23/2026Positive
Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth
Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.
Seeking Alpha7/21/2026Positive
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
Zacks Investment Research7/8/2026Positive
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Zacks Investment Research6/23/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FMS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026